AzTrials
AzTrials

Postoperative PainPhase 4NCT03052673

Ketamine for Pain Relief in Bariatric Surgery

A Phase 4 study testing Fentanyl and ketamine in people with Postoperative Pain, run by Sir Ganga Ram Hospital at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The surgical interventions for treating morbid obesity, i.e. bypass procedure and sleeve gastrectomy are collectively covered under the term 'bariatric surgery'. The growth of bariatric surgery has seen consonant development of anaesthesia techniques so as to ensure patient safety and facilitate post-surgery outcome. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Postoperative Pain
What is being tested?
Fentanyl and ketamine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
76 participants
Where
1 siteIndia
Study dates
20 Feb 2017to 30 Jul 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients of age 18-60 years
  • BMI > 35 kg/m2
  • Either sex
  • ASA physical status II \& III
  • undergoing laparoscopic bariatric surgery

Who cannot join

  • Patients refusal
  • ASA physical status: IV
  • History of hypersensitivity to fentanyl and/or ketamine
  • Chronic opioid use
  • History of substance abuse
  • Metabolic disorders
  • Seizure disorder

Trial locations and contacts

1 site in 1 country.

India1 site
  • Sir Ganga Ram Hospital

    New Delhi, 110060

Other trials in India

About this study

Official title: Per-operative Low-Dose Ketamine For Postoperative Pain Relief In Patients Undergoing Bariatric Surgery: A Randomised Study

The surgical interventions for treating morbid obesity, i.e. bypass procedure and sleeve gastrectomy are collectively covered under the term 'bariatric surgery'. The growth of bariatric surgery has seen consonant development of anaesthesia techniques so as to ensure patient safety and facilitate post-surgery outcome. Conventionally, balanced general anaesthesia techniques routinely use opioids peri-operatively for intra-operative haemodynamic homeostasis and postoperative pain relief. However, since the morbidly obese patients have high prevalence of obstructive sleep apnea(OSA) and other co-morbidities the same technique when employed in the morbidly obese patients hampers early and intermediate postoperative recovery due to the occurrence of side effects, such as, sedation, PONV, respiratory depression, depressed GI-mobility. The above stated side effects, have lead to increased propensity for postoperative cardiac and pulmonary complications. Obese patients are more vulnerable and sensitive to the narcotics and sedatives, these drugs need to be employed judiciously in these patients. On the other hand, the reduction in opioid use may result in acute post-operative pain that may limit post-surgery rehabilitation. Therefore, we need to minimise opioid use and employ some other drugs which besides having analgesia, has a opioid-sparing effect also.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic properties in sub-anaesthetic doses. When used in low dose (0.2mg/kg), it is an analgesic, anti-hyperalgesic, and prevents development of opioid tolerance. On a conceptual basis, a key advantage of ketamine is that it can reduces post-operative pain and use of opioid when used per-operatively. Therefore, a regimen which avoid or minimise use of opioid is likely to decrease opioid-related postoperative morbidity in these patients undergoing bariatric surgery.In view of the above, a clinical research is highly desirable to study techniques to decrease the use of opioids in obese surgical patients.This prospective randomised two-arm study aims to assess the effect of low-dose ketamine on postoperative pain relief and opioid-sparing ability in obese patients undergoing bariatric surgery.

Read the detailed description

After obtaining approval from the hospital ethics committee and written informed consent from the patients, this prospective randomised study will be conducted on 76 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 38 patients each.

Group 1[Ketamine + Fentanyl Group, n=38]: Pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intra-operative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr

Group 2[Fentanyl Group, n=38]: Pre-induction fentanyl 1-mcg/kg, saline after induction followed by intra-operative fentanyl infusion of 0.5-mcg/kg/hr + saline infusion.

Both the groups will receive intravenous PCA of fentanyl post-operatively.

Randomisation, Allocation Concealment:

The patients will be randomly allocated to one of the two groups based on a computer-generated random number table (url:stattrek.com/statistics/random-number-generator.aspx). Randomisation sequence concealment will include opaque-sealed envelopes with alphabetic codes whose distribution will be in control of an independent analyst. The envelopes will be opened; patient's data-slip will be pasted on them, and will be sent back to the control analyst.

Blinding Strategy:

The attending anaesthesiologist will be blinded to the intra-operative infusions used. Postoperative patient recovery profile will also be evaluated by an independent assess or blinded to the intra-operative anaesthesia technique.

Management of Anaesthesia:

Premedication

All patients will be receive tablet ranitidine-150 mg night before and on morning of surgery.They will be instructed to fast for at least 8- hours before surgery. Clear fluids will be allowed till 2 hours before surgery.

Intra-operative Monitoring

Two peripheral venous lines (18G/20G catheter) will be secured. Standard monitoring including 5-lead ECG, non-invasive blood pressure (NIBP), pulse oximeter, end-tidal carbon dioxide (EtCO2) and end-tidal gas monitoring will be applied. Additional monitoring will include depth of anaesthesia monitoring using Bi-spectral index (BIS) and neuromuscular monitoring using train-of-four response.

Anaesthesia Technique

All patients will be pre-oxygenated with 100% oxygen for at least 3-minutes prior to induction of anaesthesia. All the drugs (study + control) will be administered based on lean body weight (LBW). Patients in the KF group will receive pre-induction fentanyl-citrate l-µg/kg IV and ketamine 0.5-mg/kg after induction whereas patients in the Fentanyl group will receive pre-induction fentanyl-citrate l-µg/kg IV and saline as in above group. Anaesthesia will be induced with propofol 2-2.5mg/kg titrated to a BIS-value of 50.. After induction of anaesthesia, atracurium besylate 0.5-mg/kg will be administered for skeletal muscle relaxation to facilitate tracheal intubation. Ventilator settings for CMV, tracheal tube size [7.5-mm I.D (male), 6.5-mm I.D (female)], and breathing circuit (circle-CO2 absorber system) will be the standardised in all the patients. The patients in the Ketamine + Fentanyl group will receive fentanyl infusion at 0.5-mcg/kg/hr and ketamine infusion of 0.2-mg/kg/hr. The patients in the Fentanyl group will receive fentanyl infusion at 0.5-mcg/kg/hr and saline infusion. The LBW in obesity patients scheduled to undergo bariatric surgery will be calculated based on the following formulae:

9270 x TBW (kg)/6680 + (216 x BMI) [men]

9270 x TBW (kg)/8780 + (244 x BMI) [women]

Desflurane in oxygen-nitruos oxide mixture (FiO2 0.50) will be used for maintenance in both the groups to maintain a BIS of 40-60. Intra-operative muscle relaxation will be maintained using atracurium boluses controlled by train-of-four response on peripheral neuromuscular monitor. Thirty minutes before the end of surgery, non-opioid analgesics, such as paracetamol 1-gm will be administered to the patient. Desflurane delivery will be stopped at the point of completion of skin closure. Residual neuromuscular blockade (assessed with train-of-four response) will be reversed with neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg).

After discontinuation of anaesthesia delivery (0-time point) the time to eye opening and time to extubation will be determined. After tracheal extubation the patients will be shifted to postoperative recovery room adjoining OT suites and will be closely observed for oxygenation and ventilation status, pain (visual analogue score [VAS]), sedation (Modified OASS), and PONV.

Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval. A baseline visual analogue scoring will be done after shifting the patient to the recovery room (0-time point) followed by 2-hours, 4-hours, 8-hours, 12-hours, and 24-hours time points from the baseline. Any adverse effects such as hypotension/ hypertension, bradycardia/tachycardia, hypoxemia, giddiness will be recorded and treated. Post-surgery, time to alimentation post surgery will be noted.

'Rescue' pain relief drug will include: diclofenac sodium 75 mg slow IV bolus for NRS>3 and 'rescue' antiemesis agent would be ondansetron 4-mg for a PONV score > 1.

Being tested
Fentanyl, ketamine
Keywords
ketamine, fentanyl, postoperative pain
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FentanylDrug

    Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms

  • ketamineDrug

    Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm

Study groups in NCT03052673
Study groupRoleWhat they receive
Ketamine + Fentanyl GroupActive comparatorPatients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr. Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval.
Receives: Drug: Fentanyl; Drug: ketamine
Fentanyl GroupActive comparatorPatients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr. Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval.
Receives: Drug: Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Efficacy of Postoperative Analgesia

    will be assessed using visual analogue scale (VAS) score

    Measured: From end of anaesthesia till 24-hours postoperatively

  2. Postoperative Fentanyl Consumption in micrograms

    Amount of fentanyl consumed using the IV-PCA pump will be calculated

    Measured: From end of anaesthesia till 24-hours postoperatively

Secondary outcomes (6)
  1. Time to eye opening in minutes

    Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted

    Measured: From end of anaesthesia till 20-minutes postoperatively

  2. Time to extubation in minutes

    Time taken for tracheal extubation after discontinuation of anaesthesia will be noted

    Measured: From end of anaesthesia till 30-minutes postoperatively

  3. Changes in intraoperative heart rate (beats per minute)

    Comparison of intraoperative heart rate between both the arms will be done

    Measured: From beginning of anesthesia (0-hours, baseline) till 6 hours intraoperatively

  4. Changes in intraoperative blood pressure- systolic, diastolic, and mean (mmHg)

    Comparison of intraoperative blood pressure- systolic, diastolic, and mean between both the arms will be done

    Measured: From beginning of anesthesia (0-hours, baseline) till 6 hours intraoperatively

  5. Postoperative Sedation

    will be assessed using Modified Observer's assessment of alertness/sedation scale (OASS)

    Measured: From end of anaesthesia till 24-hours postoperatively

  6. Postoperative Nausea and Vomiting

    will be assessed using PONV Scale

    Measured: From end of anaesthesia till 24-hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2017
  2. Study start20 Feb 2017
  3. Primary completion30 Jul 2018
  4. Study completion30 Jul 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
76 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 38 patients each. Group 1\[Ketamine + Fentanyl Group, n=38\]: Pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr. Group 2\[Fentanyl Group, n=38\]:Pre-induction fentanyl 1-mcg/kg, saline after induction followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + saline infusion. Both the groups will receive intravenous PCA of fentanyl post-operatively
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
76 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03052673
Sponsor's protocol ID
EC/01/17/1120
Status last verified
Aug 2018
First submitted
6 Feb 2017
Last updated
31 Aug 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fentanyl and ketamine in people with Postoperative Pain, run by Sir Ganga Ram Hospital at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Efficacy of Postoperative Analgesia (time frame: From end of anaesthesia till 24-hours postoperatively). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in